The World Health Organization (WHO) this Saturday recognized that some new mutations in the omigran variant of the SARS-Cov-2 virus suggest higher transmission potential compared to previous strains.
“This variation is detected faster than previous outbreaks in the number of infections, which may indicate an advantage when it comes to spreading,” the company’s experts said in a statement.
Although they have not yet indicated whether the new variant is more or less resistant to the anticovit-19 vaccine, they point out that diagnostic tests with PCR are still valid to detect it.
At a meeting of a so-called advisory panel of experts on the evolution of viruses, they warned that the appearance of this variant, which was first confirmed in a sample collected on November 9, coincides with a sharp increase in epidemics in South Africa. .
This Omigron variant has led many countries to suspend flights to South Africa, which is worrying due to the high number of mutations it provides, with about thirty detected in two weeks, not only in South Africa, but also in confirmed cases in neighboring Botswana, Hong Kong (China) or Belgium.
This Saturday, the P.1.1.529 strain spread to Europe, with two cases reported in the United Kingdom and two in Germany. Similarly, Italy and the Czech Republic confirmed the first epidemic of this variant.
Risk variants are most actively followed by WHO and global laboratories, and besides Omicron there are four more: alpha (first detected in the UK), beta (also in South Africa), gamma (Brazil) and delta (India).
They are generally associated with higher transmission speeds, although in recent months the delta has been dominated by more than three previously detected epidemics, with recent laboratory analyzes showing 99.8 percent of new global cases.
The WHO Advisory Council did not make new recommendations on travel restrictions or other preventive health measures, but called on the international scientific community to follow up on this and other variations.
In addition, on a personal level, the use of masks is a reminder of already known measures taken against previous variants such as hand hygiene, body space, good indoor ventilation, avoiding crowded places and the same immunization.
Experts do not specify at this time whether the new variant is more or less resistant to vaccines, but there are fears that this could affect the effectiveness of these drugs.
In this way, major manufacturers of anticovit-19 vaccines in the West, such as American Pfizer, Moderna and Johnson & Johnson, reported that they were already testing the effectiveness of their products against the variant found in South Africa.
With PL information